Rallybio (RLYB)

• Market cap: $85.8M
• 1 day: -0.19%
• 5 days: -0.43%
• 1 month: 3.13%
• 3 months: 10.23%
• 6 months: 243.83%
• Year to date: 185.51%
• 1 year: 295.11%
• 5 years: -89.24%
• 10 years: -85.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Employees: 7